Severe Hypertriglyceridaemia: Defining the Disease and Its Management
Part of New Horizons in Dyslipidaemia (NHD) 2026, this expert-led symposium explores the rapidly evolving landscape of hypertriglyceridaemia (HTG) and the increasingly central role cardiologists play in its identification, risk stratification, and management.
As our understanding of triglyceride-rich lipoproteins deepens, so too does recognition of their contribution to residual cardiovascular risk and acute pancreatitis. This session brings together leading experts to examine HTG across the clinical spectrum—from common mixed dyslipidaemia to rare genetic disorders while highlighting emerging therapeutic targets and practical management strategies for cardiovascular specialists.
Access the full session on demand to stay at the forefront of triglyceride management in modern cardiovascular care.
Key Learning Objectives
- Recall the mechanisms that make TGs a risk factor for atherosclerosis
- Review how elevated FCS is a major risk factor for pancreatitis
- Discuss the current clinical evidence of TG-lowering therapies in different disease states
Target Audience
- General Cardiologists
- Interventional Cardiologists
- Lipid Specialists
- Primary Care
- Endocrinologists
More from this programme
Part 1
Hypertriglyceridaemia: From Mixed Hyperlipidaemia to FCS
Dr Michos reviews the spectrum of hypertriglyceridaemia, from mixed hyperlipidaemia to familial chylomicronaemia syndrome (FCS). She examines current epidemiology and prevalence, and outlines guideline-based management strategies and emerging therapies to improve risk assessment and patient care.
Part 2
ApoC-III:An Emerging Target in HTG
Dr Gouni-Berthold explores ApoC-III as a novel therapeutic target in hypertriglyceridaemia (HTG). She reviews the limitations of conventional treatments in FCS and severe HTG (sHTG), examines clinical data supporting ApoC-III inhibition, and discusses its impact on plasma triglyceride reduction and pancreatitis risk.
| 1 session | |
| ApoC-III:An Emerging Target in HTG | Watch now |
Part 3
Management in Cardiology
Dr Tokgözoğlu defines the cardiologist’s role in managing severe hypertriglyceridaemia (sHTG), from early suspicion and diagnosis to triglyceride lowering for pancreatitis prevention. She highlights multidisciplinary coordination with gastroenterology, dietetics, and primary care, alongside real-world cardiology experience.
| 1 session | |
| Management in Cardiology | Watch now |
Part 4
Audience Q&A
The session closes with a short audience Q&A, chaired by Dr Gaudet.
| 1 session | |
| Audience Q&A | Watch now |
Faculty Biographies
Erin D Michos
Associate Professor of Medicine and Director of Women's Cardiovascular Health
Dr Erin Michos is an Associate Professor of Medicine in the Division of Cardiology at the Johns Hopkins University School of Medicine, with joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Director of Women’s Cardiovascular Heath and Associate Director of Preventive Cardiology with the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Dr Michos is an internationally known expert in Preventive Cardiology and Women’s Health and has authored over 350 publications. Her research has focused on cardiovascular disease among women; coronary artery calcium, inflammatory markers, and other novel biomarkers of cardiovascular risk; lipids; and vitamin D and other supplements. She is an Associate Editor for Circulation and the American Journal of Preventive Cardiology.
Following receipt of her medical degree from Northwestern University, Dr. Michos…
Daniel Gaudet
Dr Daniel Gaudet founded the Université de Montréal Community Genomics Medicine Center, the Lipid Research Group and the Lipid Clinic at the Chicoutimi Hospital, where he was also director of research from 2003 to 2012.
In 2000, Dr. Gaudet founded ECOGENE-21, a non-profit organisation in translational medicine and systems approach whose aim is the acquisition of new knowledge, the development and evaluation of diagnostic tools, novel treatments and technologies from research in genetics and omic sciences, and their application to clinical practice at the community level. The ECOGENE-21 Clinical Research Center operates in conjunction with Boréal Pharma Recherche Clinique and employs a workforce of some 25 qualified research assistants and professionals, all trained in Good Clinical Practices (GCP). It gathers well-equipped laboratories, and executes some 15 to 20 clinical studies each year. Its offer of services extends to acting as central laboratory and coordination…
Ioanna Gouni-Berthold
Professor of Internal Medicine
Prof Ioanna Gouni-Berthold is Professor of Internal Medicine and Head of the Lipid Research Clinic at the Policlinic for Endocrinology, Diabetes and Preventive Medicine at the University of Cologne in Germany.
Prof Gouni-Berthold received her training at prestigious Universities such as the Baylor College of Medicine and Harvard Medical School and is double board certified in Internal Medicine and Endocrinology, Diabetes and Metabolism.
Her research on lipids has been published in Journals such as the New England Journal of Medicine, Lancet, Lancet Diabetes & Endocrinology and the JAMA.
Lale Tokgözoğlu
Professor of Cardiology
Lale Tokgözoglu is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal. She chaired the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. Prof Tokgözoglu has served on the Board of the Turkish Society of Cardiology and was elected to be the first female President of the Society in its history, between 2014-2016. During that time, she worked with the Ministry of Health to develop ‘Heart Health policies’ and strategies. She also chaired the Dyslipidaemia Working Group of the Turkish Society of Cardiology.
Prof Tokgözoglu has contributed to several Guidelines and Consensus Papers on dyslipidaemia and Preventive Cardiology both in Europe and nationally. She was a member of the Steering Committee of the EUROASPIRE studies and has also served on the Board of the Prevention Association as…
Comments